Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NRX Pharmaceuticals (NRXP) Restructuring Costs (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Restructuring Costs for 2 consecutive years, with $30000.0 as the latest value for Q4 2025.

  • Quarterly Restructuring Costs rose 102.5% to $30000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.3 million through Dec 2025, down 5.32% year-over-year, with the annual reading at $36000.0 for FY2025, 103.0% up from the prior year.
  • Restructuring Costs for Q4 2025 was $30000.0 at NRX Pharmaceuticals, up from -$94000.0 in the prior quarter.
  • The five-year high for Restructuring Costs was $30000.0 in Q4 2025, with the low at -$1.2 million in Q4 2024.